Influenza A virus (IAV) is an airborne pathogen that causes significant morbidity and mortality each year. Macrophages (Mϕ) are the first immune population to encounter IAV virions in the lungs and are required to control infection. In the present study, we explored the mechanism by which cytokine signaling regulates the phenotype and function of Mϕ via epigenetic modification of chromatin. We have found that type I interferon (IFN-I) potently upregulates the lysine methyltransferase Setdb2 in murine and human Mϕ, and in turn Setdb2 regulates Mϕ-mediated immunity in response to IAV. The induction of Setdb2 by IFN-I was significantly impaired upon inhibition of the JAK-STAT signaling cascade, and chromatin immunoprecipitation revealed that both STAT1 and interferon regulatory factor 7 bind upstream of the transcription start site to induce expression. The generation of Setdb2LacZ reporter mice revealed that IAV infection results in systemic upregulation of Setdb2 in myeloid cells. In the lungs, alveolar Mϕ expressed the highest level of Setdb2, with greater than 70% lacZ positive on day 4 post-infection. Silencing Setdb2 activity in Mϕ in vivo enhanced survival in lethal IAV infection. Enhanced host protection correlated with an amplified antiviral response and less obstruction to the airways. By tri-methylating H3K9, Setdb2 silenced the transcription of Mx1 and Isg15, antiviral effectors that inhibit IAV replication. Accordingly, a reduced viral load in knockout mice on day 8 post-infection was linked to elevated Isg15 and Mx1 transcript in the lungs. In addition, Setdb2 suppressed the expression of a large number of other genes with proinflammatory or immunomodulatory function. This included Ccl2, a chemokine that signals through CCR2 to regulate monocyte recruitment to infectious sites. Consistently, knockout mice produced more CCL2 upon IAV infection and this correlated with a 2-fold increase in the number of inflammatory monocytes and alveolar Mϕ in the lungs. Finally, Setdb2 expression by Mϕ suppressed IL-2, IL-10, and IFN-γ production by CD4+ T cells in vitro, as well as proliferation in IAV-infected lungs. Collectively, these findings identify Setdb2 as a novel regulator of the immune system in acute respiratory viral infection.
IAV causes seasonal epidemics that result in significant morbidity and mortality annually. Less frequently, novel viral strains emerge and are responsible for much larger outbreaks around the globe. In the last pandemic in 2009, an estimated 300,000 people died from IAV infection or secondary complications. Since the virus rapidly evolves, a new vaccine must be developed each year. Since vaccine effectiveness can be highly variable, identifying other therapeutic targets is appealing for the treatment of severe disease in high-risk individuals such as young children, the elderly, and immunocompromised individuals. In this study, we found that the protein Setdb2 regulates the immune response to IAV via an epigenetic mechanism in Mϕ. Inhibition of Setdb2 activity was beneficial for host protection due to an amplified antiviral response, which correlated with accelerated viral clearance and less damage to the lungs. Therefore, targeting Setdb2 may be a powerful therapeutic strategy for treating severe pulmonary disease caused by IAV and potentially other viral pathogens that trigger robust IFN-I production.
Citation: Kroetz DN, Allen RM, Schaller MA, Cavallaro C, Ito T, Kunkel SL (2015) Type I Interferon Induced Epigenetic Regulation of Macrophages Suppresses Innate and Adaptive Immunity in Acute Respiratory Viral Infection. PLoS Pathog 11(12): e1005338. https://doi.org/10.1371/journal.ppat.1005338
Editor: Paul G. Thomas, St. Jude Children's Research Hospital, UNITED STATES
Received: June 3, 2015; Accepted: November 21, 2015; Published: December 28, 2015
Copyright: © 2015 Kroetz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by grants from the National Institutes of Health, AI-1007413, HL-031237, and HL-112897 (www.NIH.gov). Funding was received by SLK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
IAV is an airborne pathogen that is responsible for significant mortality in humans . Infection with seasonal strains of IAV is typically limited to the upper respiratory tract and causes mild to moderately severe respiratory disease. In contrast, highly pathogenic strains of IAV can spread to distal airways and alveolar spaces causing pneumonia that can be lethal. Alveolar macrophages (Mϕ) are the first immune population to encounter IAV virions in the lungs and are required for host protection [2–5]. Following activation, alveolar Mϕ become highly phagocytic and are a major source of proinflammatory cytokines, including type I interferon (IFN-I) [6,7]. Viral detection by pattern recognition receptors (PRRs) initiates a signaling cascade that activates interferon regulatory factor (IRF) 3 and IRF7, transcription factors involved in the initiation and amplification of the IFN-I response [8,9]. IFN-I binds to the IFN-α receptor (IFNAR) to induce the transcription of more than 300 IFN-stimulated genes (ISGs) with antiviral and immunomodulatory functions . However, the production of IFN-I and other proinflammatory cytokines must be tightly regulated to avoid respiratory failure. Cytokine-induced lung injury, rather than uncontrolled viral replication, is the most common cause of severe morbidity and mortality in individuals exposed to highly pathogenic strains of IAV [11–13].
Several other functions of resident and recruited Mϕ in infection caused by respiratory pathogens have been described. Early production of chemokines by alveolar Mϕ promotes the infiltration of inflammatory cells to the site of infection . Additionally, Mϕ directly initiate adaptive immune responses during infection. It has been shown that alveolar Mϕ rapidly transport antigen to draining lymph nodes in Streptococcus pneumoniae infection . Within the lungs, Mϕ present antigen and activate virus-specific T cells . Expression of the Notch ligand Delta-like 1 by Mϕ regulates the production of the antiviral cytokine IFN-γ by CD4+ and CD8+ T cells in IAV infection . Mϕ further enhance T cell-mediated immunity by undergoing apoptosis, resulting in cross-presentation of antigen to cytotoxic CD8+ T cells by DCs [17,18]. Finally, Mϕ play a pivotal role in the resolution of infection and restoration of an anti-inflammatory environment in the lungs. Internalization of residual infected-apoptotic cells and cellular debris by Mϕ inhibits viral dissemination and tissue damage by dampening inflammation and maintaining lung function [19–21].
Epigenetic modifications control gene transcription by altering residues in histone tails of chromatin. It has been shown that specific chromatin-modifying enzymes influence the phenotype and function of Mϕ [22–25]. The SET (Su(var)3-9, Enhancer-of-zeste, Trithorax)-domain superfamily consists of histone-modifying enzymes that transfer a methyl group from S-adenosyl-L-methionine to specific lysine residues in histone tails to either activate or block transcription . Setdb2 (SET-domain bifurcated 2) tri-methylates lysine 9 of histone H3 (H3K9me3) to silence gene expression and was first implicated in the induction of B cell chronic lymphocytic leukemia . Consistent with a recent publication by Schliehe et al., we demonstrate that cytokine-dependent signal transduction following IFN-I treatment upregulates Setdb2 in myeloid cells in a STAT1- and IRF7-dependent manner. However, despite this overlapping observation, we uncovered a role for Setdb2 in the regulation of the innate and adaptive immune system in primary IAV infection. Generation of mice lacking Setdb2 specifically in Mϕ revealed that Setdb2 controlled the recruitment of inflammatory monocytes to infected lungs and suppressed the expression of a large number of antiviral genes. Setdb2 expression by Mϕ also influenced cytokine production by CD4+ T cells, as well as proliferation of both CD4+ and CD8+ T cells in infected lungs. These results highlight the impact of histone modification in dictating the severity of infection and may represent a potential therapeutic target for controlling pulmonary infection and other diseases associated with IFN-I activity.
IFN-I upregulates the lysine methyltransferase Setdb2 in murine and human Mϕ
Specific cytokines can induce the expression of histone-modifying enzymes, which, in turn, regulate the transcription of target genes in a variety of immune responses [23,24]. Since IFN-I is rapidly produced following infection with a number of viral pathogens, we asked if IFN-I induced the expression of histone-modifying enzymes in bone marrow-derived Mϕ (BM-Mϕ). Notably, the lysine methyltransferase Setdb2 was upregulated by more than 700-fold relative to unstimulated BM-Mϕ (1.0 ± 0.17 vs. 781.0 ± 108.2; p<0.001) at 24 hours post-stimulation (Fig 1A). IFN-I-dependent induction was specific to Setdb2, as related histone methyltransferases containing a SET-domain were unaltered following cytokine stimulation (Fig 1B). To determine if the induction of Setdb2 occurred in a dose-dependent manner, BM-Mϕ were stimulated with increasing doses of cytokine. When normalized to unstimulated BM-Mϕ, a direct correlation between the concentration of IFN-I and Setdb2 transcript was observed (Fig 1C). To characterize the kinetics of Setdb2 expression, BM-Mϕ were treated with IFN-I over a time course. Setdb2 transcription peaked at 5 hours post-stimulation, began declining by 24 hours, and returned to baseline levels by 48 hours (Fig 1D). We next examined whether cytokines related to IFN-I could upregulate Setdb2. BM-Mϕ were treated with IFN-γ (type II IFN) or IFN-λ (type III IFN) in parallel with IFN-I. While IFN-γ upregulated Setdb2 relative to unstimulated cells (16.8 ± 1.48 vs. 1.0 ± 0.33; p<0.001), it was significantly less potent than IFN-I (Fig 1E).
(A) Comparison of chromatin-modifying enzymes in unstimulated (control) and IFN-I-stimulated BM-Mϕ by RT-PCR. Values on scatter plot represent log10 (ΔCt) at 24 hours post-stimulation. The gray lines represent a 4-fold change in gene expression; upregulated genes (red dots), downregulated genes (green dots). (B) RT-PCR of SET-domain superfamily genes in BM-Mϕ treated with a vehicle control (dotted line) or IFN-I for 24 hours. (C-E) RT-PCR of Setdb2 by BM-Mϕ stimulated with 1, 10, and 100 units/mL of IFN-I for 5 hours (C), stimulated with IFN-I for 5, 24, and 48 hours (D), and stimulated with IFN-I, IFN-II, and IFN-III for 5 hours (E). (B-E) Data are mean ± SEM relative to unstimulated BM-Mϕ, n = 3–4 independent experiments. (F, G) lacZ expression (F) and MFI (G) in BM-Mϕ isolated from Setdb2LacZ reporter mice was determined by flow cytometry 24 hours post-IFN-I stimulation. Data are mean ± SEM gating on CD11b+ cells, n = 3 independent experiments. (H, I) C57BL/6 (H) and Setdb2LacZ reporter (I) mice were inoculated with PBS or IAV (1 x 104 PFU). (H) RT-PCR of Ifnb1 and Setdb2 in IAV-infected lungs on day 4 post-infection. Data represent fold-change relative to uninfected lungs; data are mean ± SEM, n = 8–12 mice. (I) lacZ expression by CD11b+ cells in the lungs and spleen was determined by flow cytometry; PBS (black), IAV (red). Histograms are a representative example from 3 independent experiments (n = 8–12 mice). (J, K) RT-PCR of Setdb2 in human PBMCs (J) and M-CSF-skewed Mϕ (K) stimulated with IFN-I over the indicated time course. (L) RT-PCR of SET-domain superfamily genes in human Mɸtreated with a vehicle control (dotted line) or IFN-I for 72 hours. (M, N) RT-PCR of Setdb2 in murine AECs (M) and NHBEs (N) stimulated with IFN-I for the indicated time course. (J-N) Data are mean ± SEM relative to unstimulated cells (dotted line), n = 3–5 independent experiments. N.D.; not detected. *p<0.05; **p<0.01; ***p<0.001.
To further characterize Setdb2 expression in vitro and in vivo, we generated Setdb2LacZ reporter mice. To measure the degree of transcription from the Setdb2 promoter, a gene trap vector was used to incorporate the E. coli gene lacZ, which encodes β-galactosidase, into recombinant DNA to generate lacZ fusion transcripts as previously described . BM-Mϕ from reporter mice were treated with a vehicle control or IFN-I and β-galactosidase activity was measured by flow cytometry. At 24 hours post-stimulation, 5% of control cells expressed lacZ. IFN-I treatment increased Setdb2 expression, with more than 20% of BM-Mϕ lacZ positive (5.17 ± 0.48% vs. 22.3 ± 1.32%; p<0.001) (Fig 1F). Enhanced lacZ expression following IFN-I treatment correlated with an increase in mean fluorescent intensity (MFI) (4921 ± 35.2 vs. 6464 ± 52.3; p<0.001) (Fig 1G).
Since exposure to IAV triggers robust IFN-I production, we next characterized Setdb2 expression in a murine model of infection. On day 4 post-infection, enhanced expression of Ifnb1 correlated with a 11-fold increase in Setdb2 transcript when normalized to uninfected lungs (11.0 ± 1.38 vs. 1.0 ± 0.43; p<0.001) (Fig 1H). To confirm these data, Setdb2LacZ reporter mice were inoculated with PBS or IAV. In naïve animals, less than 10% of CD11b+ cells in the lungs were lacZ positive. IAV infection enhanced the percentage of CD11b+ cells expressing lacZ in the lungs (7.25 ± 0.14% vs. 30.8 ± 2.25%; p<0.001) (Fig 1I). In addition, Setdb2 was upregulated in the spleen following infection (7.38 ± 0.19% vs. 25.9 ± 2.37%; p<0.001) (Fig 1I). Enhanced lacZ expression by CD11b+ cells in IAV infection was accompanied by a significant shift in MFI in the lungs and spleen, respectively (2095 ± 41.3 vs. 2882 ± 29.9; p<0.001, 3576 ± 39.1 vs. 5280 ± 122.3; p<0.001).
These results prompted us to characterize SETDB2 expression in human cells. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors and stimulated with IFN-I. When normalized to unstimulated PBMCs, IFN-I treatment resulted in a 3-fold increase in SETDB2 at 5 and 48 hours post-stimulation (Fig 1J). Since we only observed a slight increase in SETDB2 in PBMCs, CD14+ monocytes were skewed toward a Mϕ phenotype and stimulated with IFN-I. Initially, IFN-I did not induce SETDB2 expression in human Mϕ. However, a slight increase was observed by 24 hours and SETDB2 expression continued to increase through 72 hours post-stimulation (Fig 1K). In contrast to murine BM-Mϕ, IFN-I upregulated SETD2, SETD5, and SUV420 in human Mϕ at 72 hours post-stimulation (Fig 1L). Despite being the primary target for IAV, Setdb2 was not induced in murine airway epithelial cells (AECs) or normal human bronchial epithelial cells (NHBEs) treated with IFN-I (Fig 1M and 1N).
Setdb2 expression by Mϕ is dependent on JAK-STAT pathway and IRF7
IFN-I signals through the JAK-STAT signaling pathway to promote the transcription of ISGs involved in antiviral immunity. This prompted us to explore the signaling pathway regulating Setdb2 transcription. We initially tested if IFN-I-dependent induction of Setdb2 was dependent on the JAK-STAT pathway using the JAK inhibitor tofacitinib . In comparison to control BM-Mϕ, Setdb2 transcript was undetected in both unstimulated and IFN-I-stimulated BM-Mϕ treated with tofacitinib (Fig 2A). Next, we examined Setdb2 expression in Stat1-/- mice since IFN-I signals predominantly through a STAT1-STAT2 heterodimer. Stimulation of wild-type BM-Mϕ with IFN-I resulted in nearly a 1500-fold increase Setdb2 transcription (1463 ± 250; p<0.001). A deficiency in Stat1 significantly dampened the induction of Setdb2, with less than a 15-fold induction relative to unstimulated BM-Mϕ (14.8 ± 4.20; p<0.001) (Fig 2B). In addition, Setdb2 expression was impaired in the lungs of Stat1-/- mice infected with IAV. On day 4 post-infection, a 90% reduction in Setdb2 transcript was observed in CD11b+ cells from Stat1-/- lungs relative to control lungs (Fig 2C).
(A-C) RT-PCR of Setdb2 in BM-Mϕ (A, B) and CD11b+ cells (C) from IAV-infected lungs. (A) Untreated and IFN-I-stimulated BM-Mϕ were treated with a vehicle control or the JAK inhibitor tofacitinib at the time of stimulation. (B) Control and Stat1-/- BM-Mϕ were stimulated with media or IFN-I for 5 hours. (A, B) Data are mean ± SEM relative to unstimulated cells; n = 3 independent experiments. (C) CD11b+ cells were isolated from the lungs of control and Stat1-/- mice inoculated with IAV (1 x 104 PFU). Data are mean ± SEM relative to control cells on day 4 post-infection; n = 8–12 mice. (D, E) RT-PCR of Irf3 (D) and Irf7 (E) in control BM-Mϕ stimulated with IFN-I for the indicated time course. Data are mean ± SEM relative to unstimulated cells; n = 2–3 independent experiments (F, G) RT-PCR of Setdb2 and Irf3/Irf7 in BM-Mϕ treated with control, IRF3, or IRF7 siRNA and stimulated with IFN-I for 24 hours. Data are mean ± SEM relative to cells treated with control siRNA; n = 3 independent experiments. (H, I) ChIP analysis of STAT1 (H) and IRF7 (I) binding in the Setdb2 promoter in control and IFN-I-stimulated BM- Mϕ after 24 hours. Data are mean ± SEM relative to IgG control; n = 2–3 independent experiments. N.D.; not detected. *p<0.05; **p<0.01; ***p<0.001.
IRF3 and IRF7 are critical transcription factors involved in IFN-I production and the induction of ISGs [30,31]. Whereas IRF3 is constitutively expressed at low levels and initiates IFN-I production after viral detection, IRF7 is an ISG that is expressed at high levels in infection and is the master regulator of the IFN-I response. Consistent with published data, stimulation of BM-Mϕ with IFN-I resulted in a dramatic upregulation of Irf7, but not Irf3 (Fig 2D and 2E). To determine if Setdb2 expression was dependent on either transcription factor, BM-Mϕ were transfected with control, IRF3, or IRF7 siRNA and stimulated with IFN-I. Silencing of IRF7, but not IRF3, resulted in a significant reduction in Setdb2 in comparison to control cells (0.44 ± 0.08 vs. 1.0 ± 0.09; p<0.01). Transcription of Irf3 and Irf7 was diminished by at least 60% and 80%, respectively, when treated with respective siRNA indicating the knockdown was successful (Fig 2F and 2G).
Since Setdb2 expression was diminished in BM-Mϕ deficient in Stat1 or treated with IRF7 siRNA, we performed ChIP to determine if these transcription factors regulated expression by binding to the Setbd2 promoter. Using published binding site sequences, we identified STAT1 and IRF7 binding sites upstream of the Setdb2 transcription start site. Prior to cytokine stimulation, STAT1 and IRF7 were absent in the Setdb2 promoter (Fig 2H and 2I). However, a dramatic increase in STAT1 and IRF7 binding was observed in BM-Mϕ stimulated with IFN-I (Fig 2H and 2I).
Setdb2 is systemically upregulated in myeloid cells in IAV infection
Since IAV infection results in the influx of inflammatory cells to the lungs, we further characterized Setdb2 expression using Setdb2LacZ reporter mice. In naïve lungs, alveolar Mϕ expressed the highest level of Setdb2, with 30% of the population lacZ positive. Less than 10% of other myeloid and lymphoid cellular populations expressed lacZ in steady-state conditions (Fig 3A). IAV infection resulted in upregulation of Setdb2 in multiple cellular populations. Similar to uninfected lungs, alveolar Mϕ were the predominant population expressing Setdb2 in IAV infection. On day 4 post-infection, the proportion of alveolar Mϕ expressing Setdb2 nearly doubled, with greater than 70% expressing lacZ (31.3 ± 1.74% vs. 74.6 ± 2.69%; p<0.001) (Fig 3A). In addition, infection enhanced lacZ expression in other myeloid populations, including inflammatory monocytes, tissue Mϕ, neutrophils, and DCs. In contrast, CD4+ T cells were the only lymphoid population to express more lacZ following infection. Comparable to naïve lungs, less than 10% of NK cells, CD8+ T cells, and B cells were lacZ positive in infected lungs (Fig 3A). IAV-dependent induction of Setdb2 transcription was not limited to the lungs, as lacZ expression was significantly elevated in inflammatory monocytes in the blood (6.51 ± 1.16% vs. 46.3 ± 5.01%; p<0.01) and spleen (18.1 ± 2.48% vs. 33.9 ± 4.19%; p<0.01) (Fig 3B and 3C).
Setdb2LacZ reporter mice were inoculated with PBS or IAV (1 x 104 PFU) to determine the proportion of inflammatory populations expressing lacZ in the lungs (A), blood (B), and spleen (C) on day 0 and 4 post-infection. Leukocytes were phenotypically characterized by the following surface markers: neutrophils (Ly6Ghigh CD11b+ CD11c-), inflammatory monocytes (Ly6Chigh CD11b+ CD11c- CCR2+), alveolar Mϕ (F4/80+ CD11c+ CD11blow/- MHC-IIlow/int), tissue Mϕ (F4/80+ CD11b+ CD11c- MHC-IIhigh), conventional DCs (MHC-IIhigh CD11b+ CD11c+), NK cells (NK1.1+ CD3-), B cells (B220+ CD4- CD8-), CD4+ T cells (CD4+ CD3+), and CD8+ T cells (CD8+ CD3+). Data are mean ± SEM (n = 6–12 mice) from 2–3 independent experiments. *p<0.05; **p<0.01; ***p<0.001.
Setdb2 expression by specific myeloid populations controls the severity of IAV infection
To determine the role of Setdb2 in immunity during respiratory viral infection, we generated mice deficient for Setdb2 in myeloid cells with lysosomes (monocytes, Mϕ, and granulocytes) using the Cre-lox system. For validation, Setdb2 transcription was measured in BM-Mϕ from Setdb2ff Lyz2cre- (control) and Setdb2ff Lyz2cre+ (knockout) mice. Relative to control BM-Mϕ, a significant reduction in transcript was observed in Setdb2-/- BM-Mϕ treated with a vehicle control or IFN-I (Fig 4A). To examine if Setdb2 influenced the outcome of infection, mice were infected with a lethal dose of IAV and survival was monitored for two weeks. While both groups of mice began to succumb to infection on day 7, survival was enhanced in Setdb2ff Lyz2cre+ mice. Whereas only 20% of control mice were alive by day 9, greater than 65% of knockout mice survived (Fig 4B). To determine viral load, we quantified the number of copies of IAV proteins in the lungs. While we observed a comparable fold-increase of non-structural protein 1 (NS1) and matrix protein 1 (M1) at day 4 post-infection, Setdb2ff Lyz2cre+ lungs had a reduction in both viral proteins by day 8 post-infection (Fig 4C).
(A) RT-PCR of Setdb2 in control and Setdb2-/- BM-Mϕ treated with a vehicle control or IFN-I for 5 hours. Data are mean ± SEM from 3 independent experiments. (B) Survival of control and Setdb2ff Lyz2cre+ mice inoculated with a lethal dose of IAV (1 x 105 PFU). (C, D) Control and Setdb2ffLyz2cre+ mice inoculated with a sublethal dose of IAV (1 x 104 PFU). (C) RT-PCR of M1 and NS1 in infected lungs on day 4 and 8 post-infection. (D) Lung sections were stained with H&E on day 0 and 4 post-infection. Scale bar, 100 μm. (B-D) Data are from 3 independent experiments; n = 8–18 mice. *p<0.05; ***p<0.001.
Since tissue damage is often the cause of morbidity and mortality in IAV infection, we next examined lung histology in naïve and infected mice. Prior to infection, control and Setdb2ff Lyz2cre+ lung histology was comparable (Fig 4D). Indicative of respiratory viral infection, the airways of control lungs were filled, likely with dead epithelial and inflammatory cells, cellular debris, and virus on day 4 post-infection. In contrast, Setdb2ff Lyz2cre+ lungs had less obstruction to the airways. In addition, we observed dense clusters of lymphoid cells near blood vessels in knockout mice that were absent in wild-type lungs (Fig 4D).
Setdb2 suppresses the expression of proinflammatory and antiviral genes
IAV sensing by the innate immune system results in robust production of IFN-I and other proinflammatory cytokines and chemokines. Since knockout mice controlled infection better than their wild-type counterparts, we postulated that Setbd2 dictates the severity of infection by regulating the transcription of antiviral genes. To identify potential target genes, we screened antiviral genes in control and Setdb2-/- BM-Mϕ stimulated with IFN-I using a PCR array. In the absence of Setdb2, the overall gene profile in BM- Mϕ was altered at 24 hours post-stimulation (Fig 5A; p<0.001). A 5.8- and 6.8-fold increase in Ifna2 and Ifnb1 transcript, respectively, was observed in Setdb2-/- BM-Mϕ. Notably, the CCR2 and CCR5 ligands Ccl2 and Ccl5, respectively, were upregulated 23- and 29-fold in Setdb2-/- BM-Mϕ (Figs 5A and 6D). Additional chemokines and cytokines, including Cxcl1, Cxcl2, Cxcl9, Cxcl10, Cxcl11, Il1b, Il6, Il10, Il12a, Il12b, and Il15 were upregulated by 2-fold or more in the absence of Setdb2. To confirm the cytokine transcription data, we measured the concentration of select cytokines in the supernatants of BM-Mϕ stimulated with IFN-I. Consistently, more IL-1β, IL-6, IL-10, IL-12p40, and G-CSF were detected in the absence of Setdb2. TNF-α transcript and protein was the only cytokine examined that was reduced in Setdb2-/- BM-Mϕ (Fig 5B).
Gene expression (A, C) and cytokine production (B) by control and Setdb2-/- BM-Mϕ stimulated with IFN-I for 24 hours. Data represents the mean ± SEM of 3 independent experiments. (A) Comparison of antiviral and proinflammatory genes by RT-PCR. Values on scatter plot represent log10 (ΔCt). The gray lines represent a 2-fold change in gene expression; upregulated genes (red dots), downregulated genes (green dots). (B) Concentration of IL-1β, IL-6, IL-10, IL-12p40, G-GSF, and TNF-α in the supernatants of control and Setdb2-/- BM-Mϕ. (C) RT-PCR of Isg15 and Mx1. Data were normalized to control BM-Mϕ. (D-G) Control and Setdb2-/- BM-Mϕ were treated with a vehicle control, IFN-I (D-G), or IFN-II (F, G) for 24 hours. Data are mean ± SEM relative to IgG control; n = 2–3 experiments (D, E) ChIP analysis of Setdb2 binding and H3K9 tri-methylation in the Isg15 (D) and Mx1 (E) promoter. (F, G) ChIP analysis of STAT1 (F) and IRF7 (G) binding in the Mx1 promoter. (H) Control and Setdb2ff Lyz2cre+ mice inoculated with a sublethal dose of IAV (1 x 104 PFU).) RT-PCR of Rnasel, Pkr, Mx1, and Isg15 in infected lungs on day 4 post-infection. Data are mean ± SEM (n = 6–14 mice) from 2–3 independent experiments. *p<0.05; **p<0.01; ***p<0.001.
(A-C) Control and Setdb2ff Lyz2cre+ mice were inoculated with IAV (1 x 104 PFU) for 4 days. (A) The absolute number of inflammatory populations in IAV-infected lungs. Cells were surface stained for the following markers: neutrophils (Ly6Ghigh CD11b+ CD11c-), inflammatory monocytes (Ly6Chigh CD11b+ CD11c- CCR2+), alveolar Mϕ (F4/80+ CD11c+ CD11blow/- MHC-IIlow/int), tissue Mϕ (F4/80+ CD11b+ CD11c- MHC-IIhigh), conventional DCs (MHC-IIhigh CD11b+ CD11c+), NK cells (NK1.1+ CD3-), B cells (B220+ CD4- CD8-), CD4+ T cells (CD4+ CD3+), and CD8+ T cells (CD8+ CD3+). (B) RT-PCR of Ccl2 in IAV-infected lungs. Values represent fold-change relative to control lungs. (C) CCL2 protein concentration in IAV-infected lungs. (A-C) Values represent mean ± SEM (n = 6–12 mice) from 2–3 independent experiments. (D-F) Control and Setdb2-/- BM-Mϕ were stimulated with IFN-I for 24 hours. (D) RT-PCR of Ccl2 in BM-Mϕ Data are mean ± SEM relative to control BM-Mϕ, n = 3 independent experiments. (E, F) ChIP analysis of Setdb2 binding (E) and H3K9 tri-methylation (F) in the Ccl2 promoter. Values represent fold-change relative to IgG controls. Values represent mean ± SEM from 2–3 independent experiments. *p<0.05; **p<0.01.
IFN-I induces the expression of ISGs that inhibit viral replication and spreading [32,33]. Elevated Ifna2 and Ifnb1 in Setdb2-/- BM-Mϕ correlated with a 22.7- and 8.5-fold increase in Isg15 and Mx1 transcript, respectively (Fig 5C). Since Setdb2 silences gene expression, we performed ChIP to determine the presence of Setdb2 and H3K9me3 in the promoter region of both genes. In control BM-Mϕ, IFN-I stimulation resulted in a 40- and 300-fold increase in Setdb2 bound to the Isg15 and Mx1 promoters, respectively (Fig 5D and 5E). This correlated with high levels of H3K9me3 in the promoter region of both genes (Fig 5D and 5E). Relative to control BM-Mϕ a significant reduction in Setdb2 and H3K9me3 was observed in Setdb2-/- BM-Mϕ (Fig 5D and 5E). In addition to less Setdb2 and H3K9me3, enhanced Mx1 expression in Setdb2-/- BM-Mϕ was associated with STAT1 and IRF7 bound to the promoter (Fig 5F and 5G). This was specific to IFN-I, as stimulation with IFN-II did not increase STAT1 or IRF7 binding in the Mx1 promoter (Fig 5F and 5G). To determine if enhanced survival and a reduced viral load was associated with an enhanced antiviral response, RNA was isolated from the lungs on day 4 post-infection. Consistent with BM-Mϕ data, Ifna2 (1.36 ± 0.27 vs. 33.1 ± 20.8; p<0.05) and Ifnb1 (1.47 ± 0.36 vs. 488.9 ± 241.4; p<0.05) transcript was elevated in the lungs from Setdb2ff Lyz2cre+ mice. This correlated with a 5- and 200-fold increase in Mx1 and Isg15, respectively. Heightened expression of antiviral effectors was specific to Mx1 and Isg15, as Rnasel (Ribonuclease L) and Pkr (Protein kinase R) expression was comparable in control and knockout animals infected with IAV (Fig 5H).
Setdb2 expression does not influence transcription factor activation in BM-Mϕ
An augmented antiviral response in Setdb2-/- BM-Mϕ was associated with higher expression of a variety of upstream genes linked to the JAK-STAT, TBK1-IRF7, and Iκκ-NF-κB signaling pathways (Fig 5A). This correlated with upregulation of PRRs, as well as downstream signaling molecules that drive the induction of IFN-I and other proinflammatory cytokines and chemokines. This included upregulation of Ddx58, Ifih1, Aim2, Nlpr3, Tlr3, Tlr8, Tlr9, Mavs, Irf7, Myd88, Stat1 and multiple other genes. Moreover, elevated Mx1 mRNA in knockout BM-Mϕ was associated with enhanced recruitment of STAT1 and IRF7 to the gene promoter. Thus, we postulated that Setdb2 indirectly suppresses proinflammatory gene expression by inhibiting the activation and nuclear translocation of transcription factors. Despite a 3.4-fold increase in Stat1 mRNA (Fig 5A), no difference in total STAT1 protein based on absorbance at 450-nm was observed in knockout BM-Mϕ stimulated treated a media alone (2.31 ± 0.12 vs. 2.39 ± 0.09) or IFN-I (2.32 ± 0.07 vs. 2.30 ± 0.11). At 30 minutes post-cytokine treatment, we unable to detect phosphorylated STAT1 in whole-cell extracts in either group. In contrast to STAT1, a higher concentration of NF-κB p65 protein was detected in knockout BM-Mϕ (211.4 ± 17.64 ng/mL vs. 290 ± 16.6 ng/mL; p<0.01). However, no correlation between Setdb2 expression and NF-κB p65 activation was observed, as an equal concentration of phosphorylated NF-κB p65 was detected in whole-cell lysates from control and knockout BM-Mϕ treated with a vehicle control (16.92 ± 0.89 ng/mL vs. 18.84 ± 3.21 ng/mL) or stimulated with IFN-I (21.29 ± 1.27 ng/mL vs. 24.65 ± 1.66 ng/mL) for a half hour.
Setdb2 expression by myeloid cells controls inflammatory cell recruitment in IAV infection
Since several chemokines were upregulated in Setdb2-/- BM-Mϕ, we asked if Setdb2 controls the influx of immune cells to the lungs. Setdb2ff Lyz2cre+ mice had a 2-fold increase in the number of inflammatory monocytes and alveolar Mϕ on day 4 post-infection (Fig 6A). More CCR2+ monocytes in knockout lungs correlated with an increase in Ccl2 transcript and protein, a potent chemotactic mediator of inflammatory monocytes (Fig 6B and 6C). Similar to the lungs, Setdb2-/- BM-Mϕ stimulated with IFN-I transcribed more Ccl2 than control cells (Fig 6D) and ChIP analysis revealed Ccl2 is a Setdb2 target gene (Fig 6E and 6F). In respect to control cells, a 10- and 30-fold reduction in Setdb2 and H3K9me3, respectively, was observed in the Ccl2 promoter in Setdb2-/- BM-Mϕ (Fig 6E and 6F).
Setdb2 expression by Mϕ influences T cell proliferation in IAV-infected lungs
Transcriptional analysis of IFN-I-stimulated BM-Mϕ identified Setdb2 as a negative regulator of antiviral immunity. This included the suppression of a number of cytokines and chemokines implicated in the migration and subsequent activation of T cells in the lungs following viral infection (Fig 5A and 5B). Although the number of CD4+ and CD8+ T cells in IAV-infected lungs was comparable on day 4 post-infection (Fig 6A), it is possible that this time point occurred prior to the initiation of the adaptive immune system. This is supported by the observation that reduced disease severity in Setdb2ff Lyz2Cre+ mice was not observed until day 8 post-infection. To address this concern, control and Setdb2ff Lyz2Cre+ mice infected with a sublethal dose of IAV were euthanized on days 6, 8, and 10 post-infection to determine the proportion and number of T cells in the lungs. In both groups, the proportion of CD4+ T cells represented 10 to 15% of cells in the lungs at all days examined. A very modest, yet significant increase in CD4+ T cells was observed in knockout lungs in comparison to controls (9.73 ± 0.70% vs. 12.90 ± 1.02%; p<0.05). In contrast, the proportion of CD8+ T cells increased over time in IAV-infected lungs. On day 6 post-infection, the proportion of CD8+ T cells were comparable in control and mutant lungs, with CD8+ T cells composing approximately 6% of total cells. Relative to wild-type mice, knockout mice had an increase proportion of CD8+ T cells in the lungs on day 8 (13.25 ± 1.00% vs. 16.87 ± 0.79%; p<0.01) and day 10 (15.92 ± 1.44% vs. 21.32 ± 1.37%; p<0.05). Despite only modest changes in the percentage of T cells, the absolute number of T cells was significantly altered in the absence of myeloid Setdb2. Notably, Setdb2ff Lyz2Cre+ mice had 3 times the number of both CD4+ T cells (5.81 ± 0.50 x 105 vs. 15.43 ± 0.84 x 105; p<0.001) and CD8+ T cells (3.82 ± 0.37 x 105 vs. 9.69 ± 0.59 x 105; p<0.001) in the lungs on day 6 post-infection. While the number of both T cell populations were similar in control and knockout lungs on day 8 post-infection, a 2-fold increase in CD8+ T cells (6.54 ± 1.05 x 105 vs. 11.80 ± 1.47 x 105; p<0.01) was observed on day 10 in mice lacking Setdb2 (Fig 7A).
(A, B) Control and Setdb2ff Lyz2cre+ mice infected with 1 x 104 PFU of IAV and euthanized on days 6, 8, and 10 post-infection. (A) The number of CD4+ and CD8+ T cells in IAV-infected lungs. (B) To measure proliferation, mice were injected with the thymidine analogue EdU one day prior to euthanization. The number of proliferating (EdU+) CD4+ and CD8+ T cells was calculated over the indicated time course. Values represent mean ± SEM (n = 5–20 mice) from 2–4 independent experiments. *p<0.05; **p<0.01; ***p<0.001 (relative to control lungs).
Following homing to the lungs, IAV triggers the activation and subsequent expansion of T cells at the site of infection. Since knockout mice had a greater number of both CD4+ and CD8+ T cells, we asked whether changes in proliferative capability contributed to the altered T cell prolife in IAV-infected lungs. To determine the extent of expansion, IAV-infected mice were injected with EdU (5-ethynyl-2'-deoxyuridine) and euthanized on the indicated days. While proliferation of both CD4+ and CD8+ T cells peaked on day 8 post-infection, the extent of EdU incorporation was significantly higher in knockout lungs. In wild-type lungs, 39.55 ± 2.06% of CD4+ T cells and 34.72 ± 2.20% of CD8+ T cells were EdU positive. In the absence of myeloid Setdb2, EdU incorporation was enhanced by greater than 10% in both CD4+ T cells (39.55 ± 2.06% vs. 51.00 ± 2.62%; p<0.01) and CD8+ T cells (34.72 ± 2.20% vs. 48.20 ± 1.83%; p<0.01). In contrast, gating on either CD4+ or CD8+ T cells on days 6 and 10 post-infection revealed no changes in the extent of EdU incorporation between the two groups of animals. However, despite this observation, the absolute number of proliferating T cells was enhanced on two or all three time points depending on the T cell subset. In respect to controls, knockout lungs had approximately 3 x 105 and 1 x 105 more CD4+ EdU+ T cells in the lungs on days 6 and 8 post-infection, respectively. Similarly, Setdb2ff Lyz2Cre+ mice had a greater number of CD8+ EdU+ T cells in the lungs at each time point examined. The greatest difference in cell number was observed on day 8 post-infection (2.60 ± 0.34 x 105 vs. 4.44 ± 0.47 x 105; p<0.01), with nearly 2 x 105 more proliferating CD8+ T cells in IAV-infected lungs. A significant increase in the number of CD8+ EdU+ T cells was also observed in knockout lungs on day 6 (0.99 ± 0.11 x 105 vs. 2.32 ± 0.66 x 105; p<0.05) and day 10 (2.22 ± 0.44 x 105 vs. 3.95 ± 0.52 x 105; p<0.05) post-infection (Fig 7B).
Setdb2 expression by Mϕ influences antigen-specific cytokine production by CD4+ T cells
Mϕ, along with DCs and B cells, process and subsequently present viral antigen to CD4+ T cells to stimulate the production of cytokines with antiviral and/or immunomodulatory activity. This prompted us to ask whether Setdb2 expression by Mϕ influences antigen presentation and downstream T cell responses. Since this process is dependent on the expression of MHC class II, as well as several co-stimulatory molecules, we initially examined cell surface markers on IFN-I-stimulated BM-Mϕ by flow cytometry. The level of MHC class II, CD40, and CD86 expression on the cell surface was comparable in both groups. In contrast, changes in IFNAR and CD80 expression were observed in the absence of Setdb2. Based on MFI, IFNAR was reduced (959.0 ± 7.0 vs. 679.5 ± 10.5; p<0.001) and CD80 was elevated (1868.0 ± 8.0 vs. 2464.8 ± 58.4; p<0.001) in Setdb2-/- BM-Mϕ stimulated with IFN-I. Despite similar levels on the cell surface, greater than a 2-fold increase in Cd40 and Cd86 transcript was detected in Setdb2-/- BM-Mϕ stimulated with IFN-I (Fig 5A).
To examine antigen-specific T cell responses, CD4+ T cells from naive OT-II mice were cultured alone or at a 5:1 ratio with either wild-type or Setdb2-/- BM-Mϕ stimulated with IFN-I in the presence of ovalbumin peptide. When co-cultured with either control or knockout BM-Mϕ, CD4+ T cells produced more IL-2, IL-5, IL-10, and IL-17 (Fig 8A). While the concentration of IL-5 and IL-17 was comparable between groups, the absence of Setdb2 in BM-Mϕ was associated with enhanced IL-2 and IL-10 production (Fig 8A). In contrast, IFN-γ production was only enhanced in co-cultures containing Setdb2-/- BM-Mϕ (Fig 8A). This correlated with a 4-fold increase in IFN-γ relative to CD4+ T cells cultured alone or with control BM-Mϕ. IL-4 was the only cytokine examined that was unaltered in all experimental conditions (Fig 8A).
(A) CD4+ T cells isolated from OT-II mice were cultured with ovalbumin peptide in the absence or presence of control or Setdb2-/- BM-Mϕ. The concentration of IL-2, IL-4, IL-5, IL-10, IL-17, and IFN-γ in supernatants was measured 48 hours after plating. Values represent mean ± SEM from 3–4 independent experiments. *p<0.05; **p<0.01; ***p<0.001.
This study uncovered a novel role for a histone-modifying enzyme in regulating immunity in acute respiratory viral infection. We have demonstrated IFN-I-dependent induction of Setdb2 in myeloid cell, most notably alveolar Mϕ and inflammatory monocytes, controls the severity of IAV infection by suppressing innate and adaptive immune responses.
Robust production of IFN-I is required to control infection with several viral pathogens. IFN-I signaling results in the transcription of ISGs involved in antiviral immunity. We identified IFN-I as a potent inducer of Setdb2 expression in Mϕ. The induction of Setdb2 by IFN-I was dependent on the JAK-STAT pathway, as blocking JAK1 or STAT1 activity diminished expression. IFN-γ and IFN-λ also signal through STAT1; however, these cytokines had little to no effect on Setdb2 expression, suggesting a downstream molecule in the signaling cascade drives IFN-I-dependent expression. In addition to STAT1, the transcription factor IRF7 regulated Setdb2 expression in in BM-Mϕ. While both STAT1 and IRF7 bound to the Setdb2 promoter, it is unclear if the transcription factors independently regulate transcription or work in concert for optimal expression. It is somewhat unexpected that IFN-λ did not upregulate Setdb2 since IFN-I and IFN-III have overlapping roles in viral infection and despite signaling through different receptors, initiate a similar signaling cascade resulting in ISGF3 activation . The degree of Setdb2 transcription correlated with the concentration of IFN-I, suggesting the extent of expression may be a useful biomarker for determining the severity of infection and autoimmune diseases that result in copious IFN-I production.
Alveolar Mϕ are the first line of defense against inhaled pathogens and are required to control IAV infection [2–5]. We found that the majority of alveolar Mϕ in IAV-infected lungs expressed Setdb2 and mice deficient for Setdb2 in Mϕ displayed prolonged survival when challenged with a lethal dose of IAV. One mechanism by which alveolar Mϕ control infection is through the production of IFN-I, which, in turn, induces the expression of antiviral effectors that inhibit viral replication and dissemination. It is well documented that IFN-I-driven induction of Mx1, a dynamin-like GTPase that blocks viral transcription and replication, is critical for controlling IAV infection . In addition to Mx1, the ubiquitin-like protein ISG15 has been shown to have an important role in protecting cells from viral pathogens. In IAV infection, ISG15 limits viral replication by binding to the N-terminal RNA-binding domain of NS1, blocking nuclear import . Setdb2 selectively repressed the expression of Mx1 and Isg15 in BM-Mϕ stimulated with IFN-I and accelerated viral clearance in Setdb2ff Lyz2cre+ lungs correlated with enhanced transcription of both genes. Thus, by regulating the expression of specific ISGs, Setdb2 dictated the severity of infection. Since the selectivity of the identified Setdb2-regulated antiviral genes is not limited to IAV, it is plausible that Setdb2 controls the resolution of infection caused by other viral pathogens.
IFN-I upregulated Setdb2 in dose-dependent manner and, in turn, Setdb2 regulated the amplitude of the IFN-I response. We propose three mechanisms by which Setdb2 may repress the expression of IFN-I and downstream ISGs. First, Setdb2 regulated the expression of key transcription factors in the IFN-I signaling cascade, including Stat1 and Irf7. Second, Setdb2 may control the antiviral response by regulating the expression of PRRs since viral sensing by the innate immune system results in cytokine and chemokine production. Enhanced expression of the RNA helicases Ddx58 and Ifih1, as well as downstream genes including Tbk1, Mavs, Myd88, Irf7, among others was observed in Setdb2-/- BM-Mϕ This finding suggests Setdb2 suppresses these genes to weaken the IFN-I response. Third, in addition to targeting viral proteins, ISG15 can bind to IFN-associated transcription factors and antiviral effectors to enhance innate immunity [37–39], suggesting Setdb2-dependent regulation of ISG15 may reduce the stability of components involved in IFN-I production and downstream responses. Although IFN-I is essential for controlling IAV infection, its production must be tightly regulated to prevent tissue damage. Multiple genes involved in the suppression of IFN-I were upregulated in parallel with Ifna2 and Ifnb1 in Setdb2-/- BM-Mϕ. One example is Pin1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1), which negatively regulates the antiviral response by promoting the degradation of IRF3 . The transcription factor Foxo3 (Forkhead box O3) negatively regulates the expression of antiviral genes by forming a regulatory circuit involving IRF7 and IFN-I . The expression profile of antiviral genes in Setdb2-/- BM-Mϕ closely mimicked Foxo3-/- BM-Mϕ. This includes enhanced expression of Ccl5, Irf7, Ifnb1, Ddx58, Stat1, as well as additional ISGs suggesting Setdb2 may have a similar role in balancing the beneficial and detrimental consequences of IFN-I.
In addition to IFN-I, Setdb2 influenced the expression of proinflammatory cytokines and the immunoregulatory cytokine IL-10. Of the cytokines examined, TNF-α was the only one repressed in Setdb2-/- BM-Mϕ. This finding is of interest based on reports demonstrating cross-regulation of IFN-I and TNF-α. It is unclear whether Setdb2 promotes TNF-α expression directly or indirectly through other proteins that regulate transcription and/or translation. Since tri-methylation of H3K9 imprints a repressive mark in chromatin, it is unlikely that Setdb2 directly induces Tnf transcription. Indirect regulation of TNF-α may be cytokine-dependent, as reduced TNF-α was associated with overexpression of IFN-I and IL-10. While it is unclear if IFN-I itself can directly suppress TNF-α expression, IL-10 dampens expression by inhibiting the activation of NF-κB . Another possibility is that Setdb2 influences TNF-α expression by regulating proteins that repress transcription. For example, Twist proteins bind to the Tnf promoter to inhibit transcription and IFN-I suppresses expression by activating the receptor tyrosine kinase Axl upstream of Twist1/2 . Finally, IFNs can suppress TNF-α expression in Mϕ by promoting tristetraprolin-mediated mRNA decay in a STAT1- and p38-dependent manner, suggesting Setdb2 may negatively regulate the expression of tristetraprolin or similar proteins . Although IAV infection results in robust TNF-α production, it is unnecessary for viral clearance. Rather, TNF-α, along with Nos2, is the major culprit of immunopathology [45,46]. Furthermore, imbalanced production of either IFN-I or TNF-α is linked to autoimmunity. Rheumatoid arthritis patients, as well as children with chronic arthritis being treated with TNF-α antagonists can develop lupus-like symptoms due to overexpression of IFN-α and ISGs [47,48]. Therefore, targeting Setdb2 in parallel with anti-TNF-α therapy may be beneficial for repressing exaggerated IFN-I activity in autoimmunity.
Mortality in individuals exposed to highly pathogenic strains of IAV is often due to lung injury, rather than uncontrolled viral replication. Infection caused by respiratory pathogens that target epithelial cells results in significant cell death and as a consequence, the airways become clogged with dead cells, cellular debris, surfactant material, and virus. Respiratory failure characterized by defective gas exchange and fatal hypoxia is observed in mice lacking alveolar Mϕ , highlighting the importance of sustained Mϕ viability in infection. Consistent with reports demonstrating that the level of morbidity in IAV infection is dependent on the number of resident Mϕ [49,50], a greater number of alveolar Mϕ in Setdb2ff Lyz2cre+ mice correlated with less damage to the airways and prolonged survival. There are several potential mechanisms by which Setdb2 may dictate the number of alveolar Mϕ. First, fewer alveolar Mϕ in control mice may indicate Setdb2 regulates genes that promote cell death. In IAV infection, the majority of resident Mϕ are depleted by one week due to necrosis , indicating Setdb2 expression by alveolar Mϕ may facilitate the necrotic process. Elevated Ccl5 expression may promote Mϕ survival since the CCL5-CCR5 nexus inhibits apoptosis. Accordingly, mortality is increased in Ccl5-/- or Ccr5-/- in IAV infection . Second, Setdb2 may inhibit Mϕ proliferation by suppressing local GM-CSF production . Third, since alveolar Mϕ can arise from blood monocytes , enhanced infiltration in the absence of Setdb2 may re-populate the number of alveolar Mϕ in IAV infection. Furthermore, since the removal of apoptotic cells, cellular debris, and surfactant material limits tissue damage, Setdb2 may control the extent of injury by diminishing the phagocytic capacity of Mϕ. Collectively, Setdb2 expression by Mϕ may control IAV-induced lethality by regulating airway integrity and minimizing tissue damage.
Alveolar Mϕ are a major source of chemokines following infection and as a result, promote the infiltration of inflammatory cells to the lungs. The CCR2-CCL2 axis regulates the emigration of monocytes from the bone marrow and subsequent recruitment to infectious sites . An enhanced number of CCR2+ monocytes correlated with more CCL2 in Setdb2ff Lyz2Cre+ lungs and Setdb2 directly regulated Ccl2 transcription in BM-Mϕ However, despite this clear correlation, it does not exclude the possibility that Setdb2-/- cells are highly potent in chemotaxis. In tissue, monocytes differentiate into DCs and exudate Mϕ and these cells are linked to severe disease due to overwhelming proinflammatory cytokine production [45,46,55,56]. In contrast, we found that enhanced monocyte recruitment was associated with prolonged survival. How knockout mice avoided immunopathology needs to be further explored. Although the aforementioned studies implicate monocyte-derived cells as the culprit of IAV-induced tissue damage and death, others have shown that tissue Mϕ can restore lung homeostasis and limit injury by developing an immunoregulatory phenotype that resembles that of alveolar Mϕ . In addition to monocytes, neutrophils cause significant tissue damage in IAV infection. It has been proposed that IFN-I-dependent generation of monocytes attenuates neutrophil infiltration and as a consequence, reduces tissue damage . Consistent with a recent study, the absence of Setdb2 in BM-Mϕ resulted in increased expression of neutrophil chemoattractants . However, neutrophil recruitment was comparable in control and Setdb2ff Lyz2Cre+ lungs. This inconsistency may be due to the model system, as neutrophils are more critical in bacterial infection. Moreover, the mouse strain used may account for the discrepancy. Whereas they used mice deficient for Setdb2 in all cells, our mice specifically lacked Setdb2 in monocytes, Mϕ, and granulocytes.
In addition to their central role in innate immune responses, Mϕ are involved in the initiation and maintenance of the adaptive immunity. Resident and recruited Mϕ populations can present antigen to CD4+ T cells and we showed that Setdb2 expression by Mϕ suppresses T cell proliferation and cytokine production. In IAV infection, Th1 cells are characterized by co-production of IFN-γ and IL-10 [60,61] and CD4+ T cells cultured with Setdb2-/- BM-Mϕ secreted more of both cytokines. In addition to IFN-γ and IL-10, CD4+ T cells produced more IL-2, which likely contributes to enhanced T cell proliferation in infected lungs. Whether Setdb2 expression regulates CD4+ T cell responses through antigen presentation is unclear. Several lines of evidence suggest that Setdb2 may regulate the magnitude of T cell responses indirectly through altered cytokine and chemokine production. The polarization of naïve CD4+ T cells to Th1 cells is dependent on IL-12 and Setdb2-/- BM-Mϕ secreted more IL-12p40 than control cells. Moreover, IFN-I and CCL5 can upregulate the expression of co-stimulatory molecules on antigen presenting cells, as well as regulate the phenotype of CD4+ T cells by promoting cytokine production and proliferation [62–66]. Since transcription of both genes was enhanced in the absence of Setdb2, heightened IFN-I and CCL5 production may further amplify CD4+ T cell responses. Other lymphoid populations, including CD8+ T cells and B cells, are important for the eradication of virus. Respiratory pathogens can trigger the formation of densely packed clusters of lymphocytes known as inducible bronchus associated lymphoid tissue (BALT). In IAV infection, BALT primes virus-specific T and B cells in the lungs and as a result, accelerates viral clearance . Lung histology revealed the presence of potential lymphoid structures in infected Setdb2ff Lyz2cre+ mice, but not control animals. Future studies are required to determine if the accumulation of lymphoid cells in knockout lungs is in fact BALT and if it facilitates prolonged survival.
Understanding why a host would upregulate a histone-modifying enzyme that suppresses antiviral immunity is a challenging question. One possible reason is IAV hijacks host machinery to ‘turn on’ Setdb2, thereby diminishing IFN-I expression and downstream responses to evade the immune system. By mimicking a sequence in the tail of histone H3, the viral protein NS1 allows H3N2 to utilize transcriptional regulators to suppress the antiviral response . Additionally, NS1 allows IAV to evade the immune system by preventing apoptosis through PI3K (phosphatidylinositide 3-kinase) activation and limiting IFN-β production by inhibiting IRF3 activity [69,70]. Recently, it was demonstrated that IAV escapes the IFN-I response by triggering the production of prostaglandin E2 by Mϕ, which suppresses both innate and adaptive immunity allowing the virus to replicate more efficiently . It is also plausible that even if Setdb2 suppresses antiviral immunity, it is not dramatic enough to cause significant damage to the host. IAV-associated death is rarely caused by primary infection alone. Rather, secondary bacterial pneumonia is the leading cause of mortality caused by an infectious agent . While the mechanism responsible for enhanced susceptibility to bacterial superinfection is not fully elucidated, IFN-I sensitizes the host to bacterial pneumonia [73–75]. Since Setdb2 regulates the IFN-I response in viral infection, it is possible the host has evolved to diminish the antiviral response enough to control viral infection, yet prevent secondary complications. While preparing this manuscript, it was shown that Setdb2 regulates the crosstalk between IFN-I and the NF-κB pathway to control the neutrophil response in bacterial superinfection . Together with our findings, these results implicate Setdb2 as a promising therapeutic target in respiratory viral infection and potentially, in secondary complications and autoimmune diseases linked to IFN-I activity.
Materials and Methods
All animal procedures were approved by the University Committee on the Use and Care of Animals at the University of Michigan (PRO00004191) and done in accordance with the Animal Welfare Act guidelines of the National Institutes of Health. Experiments using human samples were approved by the Institutional Review Board of the University of Michigan (HUM00075841) and conducted in accordance with the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all adult subjects.
Mice and IAV infection
C57BL/6, 129S5, and Stat1-/- mice were purchased from Taconic (Germantown, NY). B6.129P2-Lyz2tm1(cre)Ifo/J (Lyz2cre mice), and B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II) transgenic mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Setdb2 gene targeted embryonic stem (ES) cell clones EPD0164_4-B10, -E09, and -E12 were obtained from the trans-NIH Knockout Mouse Project (KOMP Repository). The JM8.N4 C57BL/6N ES cell clones  carried the knockout first tm1a(KOMP)Wtsi Setdb2 allele . The ES cells were expanded in cell culture and chromosome counts were performed. Correct targeting of the Setdb2 gene was confirmed by genetic analysis of DNA from the ES cell clones. Germline transmission of the Setdb2 tm1a allele was obtained by breeding ES cell-mouse chimeras produced by the microinjection of C57BL/6/BrdCrHsd-Tyrc albino C57BL/6 blastocysts with the ES cell clones. Chimeras were mated with FLPo recombinase mice to remove the drug selection cassette and produce mice carrying the conditional floxed Setdb2tm1c allele. C57BL/6-Tg(CAG-Flpo)1Afst/Mmucd FLPo recombinase mice  were obtained from the Mutant Mouse Resource and Research Centers (Stock Number: 032247-UCD). FLPo mice were backcrossed onto albino C57BL/6 mice so that coat color selection could be used to chimeras to identify germline transmission and maintain an inbred C57BL/6 genetic background. The resulting progeny with a floxed Setdb2 allele were bred with Lyz2cre mice to generate control and mice deficient for Setdb2 in monocytes, Mϕ, and granulocytes . Setdb2ff Lyz2cre and Setdb2LacZ reporter mice were bred in-house and genotyped with custom primers (S1 Table). For infection, the IAV strain A/PR8/34; H1N1 isotype was used (ATCC). Age-matched female mice were inoculated intranasally with 1 x 104 PFU for sublethal infection and 1 x 105 PFU for lethal infection.
Murine CD11b microbeads, human CD14 microbeads, and the murine CD4+ T cell Isolation Kit were purchased from Miltenyi Biotec. Magnetic separation yielded 95% purity of each population. PBMCs were isolated from the blood using Ficoll (GE Healthcare).
BM-Mϕ and human Mϕ differentiation
For the generation of BM-Mϕ, bone marrow was differentiated in L929 cell-conditioned media as previously described . For the differentiation of human of Mϕ, CD14+ monocytes were cultured in complete medium supplemented with 50 ng/mL of M-CSF (R&D systems) for one week. Adherent cells were washed and harvested with Trypsin/EDTA (Lonza).
Epithelial cell culture
Murine AECs were isolated from naïve mice as previously described . Briefly, Dispase-digested lungs were depleted of CD16/CD32+ and CD45+ cells using biotinylated antibodies (BD Biosciences) and anti-biotin microbeads (Miltenyi Biotec). Non-adherent cells were cultured in fibronectin-coated wells and AECs were harvested after 4 days. NHBEs and the BEGM BulletKit were purchased from Lonza. NHBEs were cultured in 25 cm2 flasks following the manufacturers recommendations. NHBEs were subcultured using Trypsin/EDTA when 80% confluent.
Cytokine and tofacitinib treatment
Murine IFN-α, IFN-β, IFN-γ, IFN-λ2, and IFN-λ3, as well as human IFN-α and IFN-β were purchased from R&D Systems. For IFN-I treatment, cells were given 10 units/mL of IFN-α and IFN-β unless otherwise noted. Cells were treated with 10 ng/mL of IFN-II (IFN-γ) or IFN-III (IFN-λ2 and IFN-λ3). For JAK inhibition, cells were treated with 50 nM tofacitinib (Cayman Chemical) at the time of stimulation.
IRF3 and IRF7 siRNA were purchased from Santa Cruz Biotechnology. Non-targeting siRNA was purchased from GE Dharmacon. BM-Mϕ were transfected with siRNA using the Amaxa Mouse Mϕ Nucleofactor Kit (Lonza). Transfected cells were cultured for 18 hours before stimulation.
Mϕ-T cell co-culture
CD4+ T cells isolated from the spleens of naïve OT-II mice were cultured alone or with BM-Mϕ at a 5:1 ratio. For cytokine analysis, co-cultures were incubated for 48 hours in the presence of 10 ng/mL of ovalbumin peptide (Peptides International).
RNA was extracted using TRIzol Reagent (Invitrogen) and cDNA was generated with the iScript cDNA synthesis kit (Bio-Rad). TaqMan primer/probe sets for murine Setdb2, Ifna2, Ifnb1, Irf3, Irf7, Ccl2, Cxcl1, Cxcl2, Il10, Tnf, Il10, Tnf, Pkr, Rnasel, Isg15, Mx1, and human SETDB2 were purchased from Applied Biosystems. NS1 and M1 were detected using custom primers . Gene expression was assessed using an ABI Prism 7500 instrument (Applied Biosystems) and normalized to Gapdh or ACTB.
The murine/human epigenetic chromatin-modifying enzyme and murine antiviral PCR arrays were purchased from SABiosciences. RNA was DNase-digested using the RNeasy Mini Kit and reverse transcribed with the RT2 First Strand Kit (Qiagen). RT-PCR was performed according to the manufacturer’s instructions and gene expression was normalized to multiple housekeeping genes.
Cytokine and chemokine production
The concentration of CCL2 was measured using the mouse CCL2 ELISA Ready-SET-Go! (eBioscience). All other cytokines were quantified using a Bio-Plex 200 (Bio-Rad Laboratories).
A total of 1 x 107 BM-Mϕ were treated with a vehicle control or cytokine for 24 hours and ChIP was performed as previously described . DNA was fragmented by sonication using a Branson Sonifier 450 (Branson Ultrasonics). For immunoprecipitation, the following antibodies were used: IRF7 (Santa Cruz Biotechnology), STAT1 (Abcam), H3K9me3 (Abcam), Setdb2 (Dr. Yali Dou, University of Michigan), and rabbit polyclonal IgG (Millipore). DNA was assessed by RT-PCR using custom primers (S2 Table).
STAT1 and NF-κB expression
For transcription factor analysis, whole-cell lysates were collected from a total of 1 x 107 BM-Mϕ treated with a vehicle control or IFN-I for 30 minutes. The concentration of protein in each sample was adjusted to a concentration of 100 μg/mL in assay buffer. Total and phosphorylated protein was measured using the following kits from abcam: STAT1 (pY701) + total STAT1 ELISA Kit, STAT1 (pS727) + total STAT1 ELISA Kit, and NF-κB p65 (pS536) + total NF-κB p65 SimpleStep ELISA Kit.
Lungs were digested in RPMI 1640-based complete medium containing 1 mg/mL of collagenase (Roche) and 30 μg/mL DNase I (Sigma-Aldrich). Samples were passed through an 18-gauge needle, filtered, stained with the LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies), blocked with anti-CD16/32, and stained with the indicated antibodies. Antibodies were purchased from eBioscience (CD11b, CD11c, F4/80, Ly6C, Ly6G, CD3, CD8, NK1.1, and IFNAR1), R&D systems (CCR2), and BD Biosciences (MHC-II, CD80, CD86, and CD40). To characterize lacZ expression, the FluoReporter LacZ Flow Cytometry Kit was used (Life Technologies). For T cell proliferation, mice were intraperitoneally given 10 mg/mL EdU one day prior to euthanization. Following surface staining, cells were labeled according to the manufacturer’s protocol. Data were acquired on a LSR II (BD Biosciences) and analyzed with FlowJo software (TreeStar).
Lungs were inflated with 10% formalin and processed using routine histological techniques. Tissue sections were stained with H&E and visualized by light microscopy.
For the survival study, the p value was determined by a log-rank survival test. Analysis of the antiviral gene profile in BM-Mϕ was characterized by one-way ANOVA. Differences for remaining experiments were analyzed by Student’s t-test or two-way ANOVA. A p value of ≤0.05 was considered significant.
S1 Table. Genotyping primers and PCR conditions.
We thank Dr. Judith Connett, Dr. William Carson, and Dr. Dipak Patel for their valuable feedback on the manuscript and Chloe Hypes for her technical assistance. We thank Dr. Thom Saunders for his assistance designing and generating the Setdb2 mice used in this study, as well as the Michigan Gastrointestinal Peptide Center (P 30-DK34933) for Transgenic Animal Core support.
Conceived and designed the experiments: DNK MAS. Performed the experiments: DNK RMA CC. Analyzed the data: DNK RMA CC. Contributed reagents/materials/analysis tools: TI MAS SLK. Wrote the paper: DNK.
- 1. Palese P (2004) Influenza: old and new threats. Nat Med 10: S82–87. pmid:15577936
- 2. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, et al. (2005) Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 79: 14933–14944. pmid:16282492
- 3. Tate MD, Pickett DL, van Rooijen N, Brooks AG, Reading PC (2010) Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice. J Virol 84: 7569–7580. pmid:20504924
- 4. Kim HM, Lee YW, Lee KJ, Kim HS, Cho SW, et al. (2008) Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J Virol 82: 4265–4274. pmid:18287245
- 5. Ito T, Allen RM, Carson WFt, Schaller M, Cavassani KA, et al. (2011) The critical role of Notch ligand Delta-like 1 in the pathogenesis of influenza A virus (H1N1) infection. PLoS Pathog 7: e1002341. pmid:22072963
- 6. Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, et al. (2007) Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 27: 240–252. pmid:17723216
- 7. Becker S, Quay J, Soukup J (1991) Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol 147: 4307–4312. pmid:1753101
- 8. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140: 805–820. pmid:20303872
- 9. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772–777. pmid:15800576
- 10. Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623–15628. pmid:9861020
- 11. Doherty PC, Turner SJ, Webby RG, Thomas PG (2006) Influenza and the challenge for immunology. Nat Immunol 7: 449–455. pmid:16622432
- 12. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, et al. (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363: 617–619. pmid:14987888
- 13. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353: 1374–1385. pmid:16192482
- 14. Pribul PK, Harker J, Wang B, Wang H, Tregoning JS, et al. (2008) Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 82: 4441–4448. pmid:18287232
- 15. Kirby AC, Coles MC, Kaye PM (2009) Alveolar macrophages transport pathogens to lung draining lymph nodes. J Immunol 183: 1983–1989. pmid:19620319
- 16. Macdonald DC, Singh H, Whelan MA, Escors D, Arce F, et al. (2014) Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. Mucosal Immunol 7: 89–100. pmid:23715172
- 17. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86–89. pmid:9510252
- 18. Winau F, Weber S, Sad S, de Diego J, Hoops SL, et al. (2006) Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24: 105–117. pmid:16413927
- 19. Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, et al. (2005) CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 11: 1180–1187. pmid:16208318
- 20. Mok CK, Lee DC, Cheung CY, Peiris M, Lau AS (2007) Differential onset of apoptosis in influenza A virus H5N1- and H1N1-infected human blood macrophages. J Gen Virol 88: 1275–1280. pmid:17374772
- 21. Schneider C, Nobs SP, Heer AK, Kurrer M, Klinke G, et al. (2014) Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. PLoS Pathog 10: e1004053. pmid:24699679
- 22. Gallagher KA, Joshi A, Carson WF, Schaller M, Allen R, et al. (2014) Epigenetic Changes in Bone Marrow Progenitor Cells Influence the Inflammatory Phenotype and Alter Wound Healing in Type 2 Diabetes. Diabetes.
- 23. Ishii M, Wen H, Corsa CA, Liu T, Coelho AL, et al. (2009) Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114: 3244–3254. pmid:19567879
- 24. Kittan NA, Allen RM, Dhaliwal A, Cavassani KA, Schaller M, et al. (2013) Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One 8: e78045. pmid:24205083
- 25. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, et al. (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488: 404–408. pmid:22842901
- 26. Dillon SC, Zhang X, Trievel RC, Cheng X (2005) The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 6: 227. pmid:16086857
- 27. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, et al. (2001) Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res 61: 2870–2877. pmid:11306461
- 28. Skarnes WC, Auerbach BA, Joyner AL (1992) A gene trap approach in mouse embryonic stem cells: the lacZ reported is activated by splicing, reflects endogenous gene expression, and is mutagenic in mice. Genes Dev 6: 903–918. pmid:1592261
- 29. Garber K (2011) Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 29: 467–468. pmid:21654650
- 30. Honda K, Takaoka A, Taniguchi T (2006) Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25: 349–360. pmid:16979567
- 31. Paun A, Pitha PM (2007) The IRF family, revisited. Biochimie 89: 744–753. pmid:17399883
- 32. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481–485. pmid:21478870
- 33. Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559–568. pmid:18575461
- 34. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77. pmid:12483210
- 35. Verhelst J, Parthoens E, Schepens B, Fiers W, Saelens X (2012) Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly. J Virol 86: 13445–13455. pmid:23015724
- 36. Hsiang TY, Zhao C, Krug RM (2009) Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. J Virol 83: 5971–5977. pmid:19357168
- 37. Kim MJ, Hwang SY, Imaizumi T, Yoo JY (2008) Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J Virol 82: 1474–1483. pmid:18057259
- 38. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, et al. (2003) Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17: 455–460. pmid:12600939
- 39. Shi HX, Yang K, Liu X, Liu XY, Wei B, et al. (2010) Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol 30: 2424–2436. pmid:20308324
- 40. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, et al. (2006) Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 7: 598–605. pmid:16699525
- 41. Litvak V, Ratushny AV, Lampano AE, Schmitz F, Huang AC, et al. (2012) A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490: 421–425. pmid:22982991
- 42. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 135: 64–73. pmid:14678266
- 43. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, et al. (2006) Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 203: 1891–1901. pmid:16831897
- 44. Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, et al. (2006) Interferons limit inflammatory responses by induction of tristetraprolin. Blood 107: 4790–4797. pmid:16514065
- 45. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD (2008) CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 180: 2562–2572. pmid:18250467
- 46. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, et al. (2002) Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360: 1831–1837. pmid:12480361
- 47. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102: 3372–3377. pmid:15728381
- 48. Ivashkiv LB (2003) Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 36: 473–479. pmid:14984024
- 49. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA (1996) Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 97: 649–655. pmid:8609219
- 50. Huang FF, Barnes PF, Feng Y, Donis R, Chroneos ZC, et al. (2011) GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med 184: 259–268. pmid:21474645
- 51. Ghoneim HE, Thomas PG, McCullers JA (2013) Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 191: 1250–1259. pmid:23804714
- 52. Hawgood S, Akiyama J, Brown C, Allen L, Li G, et al. (2001) GM-CSF mediates alveolar macrophage proliferation and type II cell hypertrophy in SP-D gene-targeted mice. Am J Physiol Lung Cell Mol Physiol 280: L1148–1156. pmid:11350793
- 53. Landsman L, Varol C, Jung S (2007) Distinct differentiation potential of blood monocyte subsets in the lung. J Immunol 178: 2000–2007. pmid:17277103
- 54. Shi C, Pamer EG (2011) Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11: 762–774. pmid:21984070
- 55. Wareing MD, Lyon A, Inglis C, Giannoni F, Charo I, et al. (2007) Chemokine regulation of the inflammatory response to a low-dose influenza infection in CCR2-/- mice. J Leukoc Biol 81: 793–801. pmid:17179466
- 56. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N (2000) Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 156: 1951–1959. pmid:10854218
- 57. Taut K, Winter C, Briles DE, Paton JC, Christman JW, et al. (2008) Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am J Respir Cell Mol Biol 38: 105–113. pmid:17690327
- 58. Seo SU, Kwon HJ, Ko HJ, Byun YH, Seong BL, et al. (2011) Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog 7: e1001304. pmid:21383977
- 59. Schliehe C, Flynn EK, Vilagos B, Richson U, Swaminathan S, et al. (2014) The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nat Immunol.
- 60. Sun J, Madan R, Karp CL, Braciale TJ (2009) Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 15: 277–284. pmid:19234462
- 61. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL (2012) Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol 86: 6792–6803. pmid:22491469
- 62. Bacon KB, Premack BA, Gardner P, Schall TJ (1995) Activation of dual T cell signaling pathways by the chemokine RANTES. Science 269: 1727–1730. pmid:7569902
- 63. Havenar-Daughton C, Kolumam GA, Murali-Krishna K (2006) Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176: 3315–3319. pmid:16517698
- 64. Lillard JW Jr., Boyaka PN, Taub DD, McGhee JR (2001) RANTES potentiates antigen-specific mucosal immune responses. J Immunol 166: 162–169. pmid:11123289
- 65. Lee JK, Kim JK, Lee YR, Kim HS, Im SA, et al. (2005) Exposure to chemokines during maturation modulates antigen presenting cell function of mature macrophages. Cell Immunol 234: 1–8. pmid:15950960
- 66. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, et al. (2002) Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99: 3263–3271. pmid:11964292
- 67. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, et al. (2004) Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 10: 927–934. pmid:15311275
- 68. Marazzi I, Ho JS, Kim J, Manicassamy B, Dewell S, et al. (2012) Suppression of the antiviral response by an influenza histone mimic. Nature 483: 428–433. pmid:22419161
- 69. Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, et al. (2007) Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 81: 3058–3067. pmid:17229704
- 70. Talon J, Horvath CM, Polley R, Basler CF, Muster T, et al. (2000) Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 74: 7989–7996. pmid:10933707
- 71. Coulombe F, Jaworska J, Verway M, Tzelepis F, Massoud A, et al. (2014) Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 40: 554–568. pmid:24726877
- 72. Hamilton BE, Minino AM, Martin JA, Kochanek KD, Strobino DM, et al. (2007) Annual summary of vital statistics: 2005. Pediatrics 119: 345–360. pmid:17272625
- 73. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, et al. (2009) Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119: 1910–1920. pmid:19487810
- 74. Li W, Moltedo B, Moran TM (2012) Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 86: 12304–12312. pmid:22951826
- 75. Nakamura S, Davis KM, Weiser JN (2011) Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 121: 3657–3665. pmid:21841308
- 76. Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, et al. (2009) Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat Methods 6: 493–495. pmid:19525957
- 77. Ryder E, Gleeson D, Sethi D, Vyas S, Miklejewska E, et al. (2013) Molecular characterization of mutant mouse strains generated from the EUCOMM/KOMP-CSD ES cell resource. Mamm Genome 24: 286–294. pmid:23912999
- 78. Kranz A, Fu J, Duerschke K, Weidlich S, Naumann R, et al. (2010) An improved Flp deleter mouse in C57Bl/6 based on Flpo recombinase. Genesis 48: 512–520. pmid:20506501
- 79. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I (1999) Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265–277. pmid:10621974
- 80. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, et al. (2009) TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. J Clin Invest 119: 33–46. pmid:19075396
- 81. Reed M, Morris SH, Jang S, Mukherjee S, Yue Z, et al. (2013) Autophagy-inducing protein beclin-1 in dendritic cells regulates CD4 T cell responses and disease severity during respiratory syncytial virus infection. J Immunol 191: 2526–2537. pmid:23894198